Emergent BioSolutions | EBS - Frais De Vente Et D'Administration

Prix De L'Action
8.07
Variation Quotidienne
-0.06 -0.74%
Mensuellement
-24.58%
Annuel
41.33%
Q1 Prévisions
7.88




Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Akebia Therapeutics USD 25.74M 1.93M 2025-03
ALKERMES USD 187.2M 15.43M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 17.94M 17.86M 2025-09
ANI Pharmaceuticals USD 82.79M 6.13M 2025-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Coherus Biosciences USD 26.02M 8.57M 2025-03
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exact Sciences USD 491.64M 35.94M 2025-09
Exelixis USD 123.02M 19.9M 2025-12
Glaxosmithkline GBP 2.91B 817.89M 2025-09
Heron Therapeutics USD 23.34M 4.18M 2024-09
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Lexicon Pharmaceuticals USD 39.19M 7.13M 2024-06
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Myriad Genetics USD 129M 1.3M 2025-09
Nektar Therapeutics USD -0.18 0.07 2024-09
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Pacira USD 91.87M 70K 2025-12
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Xoma USD 11M 2.54M 2024-06